×
About 23,685 results

ALLMedicine™ B-cell Lymphoma Center

Research & Reviews  7,483 results

Apocynin inhibits compressive force-induced apoptosis and autophagy of periodontal liga...
https://doi.org/10.1111/odi.14296
Oral Diseases; Li B, Shi Y et. al.

Jul 1st, 2022 - This study aimed to evaluate the effect of Apocynin on compressive force-induced apoptosis and autophagy in periodontal ligament stem cells (PDLSCs). PDLSCs were subjected to a uniform compressive force of 2.0 g/cm2 for 24 h, without and with addi...

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-...
https://doi.org/10.3324/haematol.2022.280805
Haematologica Kwon M, Iacoboni G et. al.

Jul 1st, 2022 - Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T-cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety ...

Olmesartan medoxomil self-microemulsifying drug delivery system reverses apoptosis and ...
https://doi.org/10.1080/10717544.2022.2086939
Drug Delivery; Murad H, Ahmed O et. al.

Jun 30th, 2022 - Olmesartan medoxomil (OM) is an angiotensin receptor blocker. This study aimed to investigate the effects of OM self-microemulsifying drug delivery system (OMS) in trinitrobenzene sulfonic acid (TNBS)-induced acute colitis in rats. Besides two con...

Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line...
https://doi.org/10.1111/bjh.18335
British Journal of Haematology; Shargian L, Raanani P et. al.

Jun 30th, 2022 - Treatment with high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is considered standard of care (SOC) second-line treatment for relapsed or refractory large B-cell lymphoma (LBCL). However, outcomes remain suboptimal. ...

The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a bette...
https://doi.org/10.1182/bloodadvances.2022007046
Blood Advances; Tabanelli V, Melle F et. al.

Jun 30th, 2022 - T-cell/histiocyte rich large B-cell lymphoma (THRLBCL) is a rare and aggressive variant of diffuse large B cell lymphoma (DLBCL) that usually affects young to middle-aged patients, with disseminated disease at presentation. The tumor microenvironm...

see more →

Guidelines  11 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

The management of primary mediastinal B-cell lymphoma: a British Society for Haematolog...
https://doi.org/10.1111/bjh.15731
British Journal of Haematology; Cwynarski K, Marzolini MAV et. al.

Jan 5th, 2019 - The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper.|2019|Cwynarski K,Marzolini MAV,Barrington SF,Follows G,Illidge T,|adverse effects,therapeutic use,chemically induced,diagnostic imaging,t...

Guidelines for the diagnosis and management of primary central nervous system diffuse l...
https://doi.org/10.1111/bjh.15661
British Journal of Haematology; Fox CP, Phillips EH et. al.

Nov 24th, 2018 - Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma.|2018|Fox CP,Phillips EH,Smith J,Linton K,Gallop-Evans E,|diagnosis,therapy,diagnosis,therapy,

Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lym...
https://doi.org/10.1016/j.ijrobp.2017.12.005
International Journal of Radiation Oncology, Biology, Phy... Ng AK, Yahalom J et. al.

Feb 8th, 2018 - Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will s...

see more →

Drugs  11 results see all →

Clinicaltrials.gov  835 results

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04739813

Jun 24th, 2022 - Background: Combination chemotherapy with rituximab has been the mainstay of treatment for CD20-positive B-cell lymphomas. Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy, but indolent lymphomas an...

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03484702

Jun 24th, 2022 - This is a study to determine the efficacy and safety of JCAR017 in adult participants with aggressive B-cell NHL. The study will enroll participants in Europe and Japan with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS; de no...

Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT00339963

Jun 24th, 2022 - Current diagnosis of the lymphoid malignancies relies upon the morphological appearance of the cancer cells supplemented by a few molecular markers. Within a diagnostic category, the clinical courses and responses of patients to therapy are variab...

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT04933617

Jun 24th, 2022 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...

A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03136497

Jun 24th, 2022 - This is a Phase 1b, single-arm, open-label, single-center study of venetoclax (ABT-199) in combination with ibrutinib and rituximab in Subjects with Relapsed/Refractory DLBCL. The trial consists of a dose-escalation of venetoclax in combination wi...

see more →

News  1,133 results

Chronic Retiform Purpura of the Abdomen and Thighs: A Fatal Case of Intravascular Large Cell Lymphoma
https://www.mdedge.com/dermatology/article/255804/dermatopathology/chronic-retiform-purpura-abdomen-and-thighs-fatal-case
Nelson Ugwu, MD, Nour Kibbi, MD et. al.

Jun 28th, 2022 - To the Editor: Intravascular large cell lymphoma (ILCL) is a rare B-cell lymphoma that is defined by the presence of large neoplastic B cells in the lumen of blood vessels. 1 At least 3 variants of ILCL have been described based on case reports and.

FDA approves liso-cel as second-line therapy for LBCL
https://www.mdedge.com/hematology-oncology/article/255765/b-cell-lymphoma/fda-approves-liso-cel-second-line-therapy-lbcl
Sharon Worcester

Jun 27th, 2022 - Lisocabtagene maraleucel, also known as liso-cel (Breyanzi), has been approved by the Food and Drug Administration for the second-line treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). This expanded indicati.

FDA Okays Liso-cel for Second Line in Large B-cell Lymphoma
https://www.medscape.com/viewarticle/976230

Jun 27th, 2022 - Lisocabtagene maraleucel, also known as liso-cel (Breyanzi), has been approved by the Food and Drug Administration for the second-line treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). This expanded indicati...

Novel gene therapy offers hope for some lymphomas
https://www.mdedge.com/hematology-oncology/article/255338/b-cell-lymphoma/novel-gene-therapy-offers-hope-some-lymphomas
Heidi Splete

Jun 9th, 2022 - Lisocabtagene maraleucel, a novel chimeric antigen receptor (CAR) T-cell product, evoked a clinical response in patients with relapsed or refractory large B-cell lymphoma in a pilot study presented at the annual meeting of the American Society of.

Glofitamab prevails against r/r DLBCL
https://www.mdedge.com/hematology-oncology/article/255306/b-cell-lymphoma/glofitamab-prevails-against-r/r-dlbcl
Heidi Splete

Jun 9th, 2022 - Approximately half of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) treated with glofitamab showed clinical response, based on phase 2 data from 154 adults. “We know that relapsed diffuse large B-cell lymphoma has a pa.

see more →

Patient Education  1 results see all →